1. Aide
    1. Espace Client
    2. Connexion
  1. Aide
    1. Espace Client
    2. Connexion
Espace Membre Boursorama

Erreur d'authentification

Vous êtes authentifié. Nous chargeons votre espace membre.

Mot de passe oublié ?

Nouveau sur Boursorama ? Devenez membre

Identifiant/Mot de passe oublié
Si vous êtes Membre de la Communauté Boursorama, veuillez indiquer l'adresse email que vous avez fournie lors de votre enregistrement pour recevoir votre identifiant et/ou ré-initialiser votre mot de passe :

Nouveau sur Boursorama ? Devenez membre

Fermer

Forum

OXURION
2.6500 (c) EUR
-3.28% 

BE0003846632 OXUR

Euronext Bruxelles données temps différé
  • ouverture

    2.6900

  • clôture veille

    2.7400

  • + haut

    2.7300

  • + bas

    2.6500

  • volume

    22 778

  • valorisation

    101 MEUR

  • capital échangé

    0.06%

  • dernier échange

    13.12.19 / 17:35:26

  • limite à la baisse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    2.5200

  • limite à la hausse

    Qu'est-ce qu'une limite à la hausse/baisse ?

    Fermer

    2.7800

  • rendement estimé 2019

    -

  • PER estimé 2019

    Qu'est-ce que le PER ?

    Fermer

    -

  • dernier dividende

    -

  • date dernier dividende

    30.11.-1

  • Éligibilité

    PEA

    Qu'est-ce que le PEA ?

    Fermer
  • + Portefeuille

  • + Liste

Retour au sujet THROMBOGENICS (WI)

OXURION : Communiqué du 24 août (partie 1)

j.salee
25 août 200713:46

ThromboGenics – Business Update and Interim Results for the Seven Month Period Ending 30 June 2007

Leuven, Belgium - August 24, 2007 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, today announces a business update and its financial results for the seven month period ending 30 June 2007.
During this period, ThromboGenics has raised additional funds to invest in its development pipeline and has continued to make good progress with its clinical programs.

Highlights
• Successful placing of a total of 5,166,517 shares, which increased the
company’s free float to 70%, and led to an improvement in stock liquidity. As part of this placement, ThromboGenics issued 2,214,030 new shares raising a total of €23.9m. These new funds have strengthened ThromboGenics financial position, and will allow it to continue to advance the development of its product portfolio and strengthen its operations. The company’s cash position amounted to €49.3m as of 30 June 2007.
• Further progress with microplasmin for ophthalmic indications. Initiation of a Phase IIb clinical trial of microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection) in the United States, as well as the initiation of twoPhase IIa clinical trials of microplasmin in Europe, for Vitreomacular traction and diabetic macular edema (MIVI IIT and MIVI II, respectively).
• Progressed TB-402 (anti-factor VIII) into man, in collaboration with BioInvent International. TB-402 is being developed as a potential anti-coagulant for the treatment and prevention of deep vein thrombosis (DVT) and atrial fibrillation.

Financial summary
• For the December 2006 to June 2007 period, revenues amounted to €1.3m, mainly coming from out-licensing. Operating expenses were €10.5m, the majority of which were due to R&D expenses related to the microplasmin clinical development program. The net loss for the period was €8.6m.
• As of 30 June 2007, ThromboGenics had €49.3m in cash and cash
equivalents. This compared to €33.7m on 30 November, 2006, and results from the fundraising that the company completed in May 2007.
• The Group streamlined its organization with the absorption of the fully owned subsidiary Thromb-X.
Prof Désiré Collen, CEO of ThromboGenics, commenting on today’s announcement, said: “I am very pleased with the all-round progress that we have made during the first half of 2007. We have been able to attract additional funding to advance our product portfolio, and to broaden our shareholder base. I am particularly excited with the very encouraging results we have obtained with microplasmin in clinical trials targeting back of the eye diseases, and with the good progress in our early clinical
programs such as with the anti-coagulant TB-402.”

.........
Pour le reste voir le site
http://www.thrombogenics.com/html/news.html

Signaler un abus

Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement

0 réponse

Retour au sujet THROMBOGENICS (WI)

Signaler le message

Fermer

Qui a recommandé ce message ?

Fermer

Mes listes

Une erreur est survenue pendant le chargement de la liste

valeur

dernier

var.

Les Risques en Bourse

Fermer